

ONLINE SEARCH REQUEST FORM


94178

USER Ell. PerschSERIAL NUMBER 091675.323ART UNIT 1623
CM 8B19PHONE 308-4616DATE 5/15/2003

mej

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).



useful to treat androgen responsive diseases.

Point of Contact
P. Sheppard
Telephone number: (703) 308-4499

STAFF USE ONLY

COMPLETED 5/15/2003
SEARCHER
ONLINE TIME TOTAL TIME
(in minutes)
NO. OF DATABASES

SYSTEMS
☐ CAS ONLINE
☐ DARC/QUESTEL
☐ DIALOG
☐ SDC
☐ OTHER

09/675323

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:21:58 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 20 May 2003 VOL 138 ISS 21
FILE LAST UPDATED: 19 May 2003 (20030519/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
=>

=> d stat que


L3 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE
L5 156 SEA FILE=REGISTRY SSS FUL L3
L6 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
 L7 7 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
 L8 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=>
 =>

=> d ibib abs hitrn 18 1-7

L8 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:334866 HCAPLUS
 TITLE: Cosmetic composition containing a DHEA derivative and
 a soothing agent
 INVENTOR(S): Picard-Lesboueyries, Elisabeth; Burnier, Veronique
 PATENT ASSIGNEE(S): L'oreal, Fr.
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035023	A1	20030501	WO 2002-FR3510	20021014
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,			

NE, SN, TD, TG

FR 2831440 A1 20030502 FR 2001-13816 20011025

PRIORITY APPLN. INFO.: FR 2001-13816 A 20011025

AB The invention relates to a compn. contg., in a physiol.-acceptable medium, at least one DHEA deriv. and at least one agent that can inhibit at least one enzyme selected from among phospholipases A2, lipoxygenases and/or human prostaglandin synthetases. The invention also relates to the cosmetic use of said compn., particularly in order to soothe cutaneous disorders including sensitive skin, cutaneous discomfort, skin tightness, pruritus, cutaneous irritations, cutaneous swelling, redness of the skin and/or cutaneous heat sensations. The invention also relates to a soothing cosmetic treatment method comprising the topical application of one such compn. A lotion for sensitive skin contained Paeonia suffruticosa ext. 0.50, 3.beta.-acetoxy-7-keto-DHEA 0.01, propylene glycol 20.00, hydroxypropyl cellulose 3.50, and Et alc. q.s. 100.00%.

IT 250163-05-4

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)

(cosmetic compn. contg. DHEA deriv. and soothing agent)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:334636 HCAPLUS

TITLE: Methods and synthesis of compounds for the treatment of blood cell disorders and delayed adverse and unwanted effect of radiation exposure

INVENTOR(S): Ahlem, Clarence N.; Reading, Christopher; Frincke, James; Stickney, Dwight; Lardy, Henry A.; Marwah, Padma; Marwah, Ashok; Prendergast, Patrick T.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 198 pp., Cont.-in-part of U.S. Ser. No. 675,470.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003083231	A1	20030501	US 2002-87929	20020301
US 2003060425	A1	20030327	US 2001-820483	20010329
ZA 2001003845	A	20020513	ZA 2001-3845	20010511
PRIORITY APPLN. INFO.:			US 1998-109923P	P 19981124
			US 1998-109924P	P 19981124
			US 1998-110127P	P 19981127
			US 1998-112206P	P 19981215
			US 1999-124087P	P 19990311
			US 1999-126056P	P 19990323
			US 1999-137745P	P 19990603
			US 1999-140028P	P 19990616
			US 1999-145823P	P 19990727
			US 1999-414905	B2 19991008
			US 1999-161453P	P 19991025
			US 1999-449004	B2 19991124
			US 1999-449042	B2 19991124
			US 1999-449184	B2 19991124
			US 1999-461026	B2 19991215
			US 2000-535675	A2 20000323
			US 2000-586672	B2 20000601
			US 2000-586673	B2 20000601
			US 2000-675470	A2 20000928
			US 2001-272624P	P 20010301

US 2001-820483 A2 20010329
 US 2001-323016P P 20010910
 US 2001-328738P P 20011011
 US 2001-338015P P 20011108
 US 2001-340045P P 20011130
 US 2001-343523P P 20011220
 US 2000-257071P P 20001220

AB The invention relates to the use of compds. to treat a no. of conditions, such as blood cell disorders and symptoms and conditions assocd. with delayed adverse or unwanted effects of radiation therapy. Compds. that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. Methods for the synthesis of those compds. are exemplified. Formulation and dosage of those compds. are claimed.

IT 250163-05-4P 357923-34-3P 357923-35-4P
 357923-38-7P 357923-39-8P 515159-71-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(methods and synthesis of compds. for treatment of blood cell disorders and delayed adverse and unwanted effect of radiation exposure)

L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:963688 HCAPLUS

DOCUMENT NUMBER: 138:28973

TITLE: Cosmetic preparations containing new derivatives of 7-oxo-DHEA

INVENTOR(S): Dalko, Maria; Cavezza, Alexandre; Picard-Lesboueyries, Elisabeth; Renault, Beatrice; Burnier, Veronique

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1266649	A1	20021218	EP 2002-291404	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
FR 2826011	A1	20021220	FR 2001-7804	20010614
JP 2003026697	A2	20030129	JP 2002-173449	20020613
US 2003054021	A1	20030320	US 2002-170679	20020614

PRIORITY APPLN. INFO.: FR 2001-7804 A 20010614

OTHER SOURCE(S): MARPAT 138:28973

AB Cosmetic prepsns. contg. new derivs. of 7-oxo-DHEA (I) for improving the appearance of keratinic materials or prevention or treatment of skin aging, skin pigmentations, hyperseborrhea, and hair loss are claimed. Synthesis of I and cosmetic prepsns. contg. I are disclosed.

IT 250163-05-4

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
 (cosmetic prepsns. contg. new derivs. of 7-oxo-DHEA)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:695788 HCAPLUS

DOCUMENT NUMBER: 137:226941
 TITLE: Use of certain steroids for treatment of a number of conditions including blood cell deficiencies
 INVENTOR(S): Ahlem, Clarence N.; Reading, Christopher; Frincke, James; Stickney, Dwight; Lardy, Henry; Marwah, Padma; Marwah, Ashok; Prendergast, Patrick T.
 PATENT ASSIGNEE(S): Hollis-Eden Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 383 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069977	A1	20020912	WO 2002-US6708	20020301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003060425	A1	20030327	US 2001-820483	20010329
PRIORITY APPLN. INFO.:				
US 2001-272624P P 20010301				
US 2001-820483 A 20010329				
US 2001-323016P P 20010910				
US 2001-328738P P 20011011				
US 2001-340054P P 20011101				
US 2001-338015P P 20011108				
US 2001-343523P P 20011220				
US 1998-109923P P 19981124				
US 1998-109924P P 19981124				
US 1998-110127P P 19981127				
US 1998-112206P P 19981215				
US 1999-124087P P 19990311				
US 1999-126056P P 19990323				
US 1999-137745P P 19990603				
US 1999-140028P P 19990616				
US 1999-145823P P 19990727				
US 1999-414905 B2 19991008				
US 1999-161453P P 19991025				
US 1999-449004 B2 19991124				
US 1999-449042 B2 19991124				
US 1999-449184 B2 19991124				
US 1999-461026 B2 19991215				
US 2000-535675 A2 20000323				
US 2000-586672 B2 20000601				
US 2000-586673 B2 20000601				
US 2000-675470 A2 20000928				
US 2000-257071P P 20001220				

OTHER SOURCE(S): MARPAT 137:226941

AB The invention relates to the use of compds. to treat a no. of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compds. that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandro-5-ene-3.beta.-yl)-.beta.-D-glucopyranosid ronate. Formulations contg. the steroids are also exemplified.

IT 250163-05-4P 357923-35-4P 357923-38-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthetic prepn. and use of certain steroids for treatment of a no. of conditions including blood cell deficiencies)

IT 250163-05-4DP, salts, esters, ethers, amides, and prodrugs
357923-34-3DP, salts, esters, ethers, amides, and prodrugs
357923-34-3P 357923-35-4DP, salts, esters, ethers,
amides, and prodrugs 357923-36-5DP, salts, esters, ethers,
amides, and prodrugs 357923-36-5P 357923-38-7DP,
salts, esters, ethers, amides, and prodrugs 357923-39-8DP,
salts, esters, ethers, amides, and prodrugs 357923-39-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthetic prepn. and use of certain steroids for treatment of a no. of conditions including blood cell deficiencies)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:293332 HCAPLUS

DOCUMENT NUMBER: 135:211172

TITLE: Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates
AUTHOR(S): Marwah, P.; Marwah, A.; Kneer, N.; Lardy, H.
CORPORATE SOURCE: Department of Biochemistry and Institute for Enzyme Research, University of Wisconsin-Madison, Madison, WI, USA

SOURCE: Steroids (2001), 66(7), 581-595
CODEN: STEDAM; ISSN: 0039-128X


PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:211172

GI



I

AB The 7-oxo deriv. of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7.beta.-hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronosides, ethers and carbonate esters. The syntheses of these compds. are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivs., e.g. I, were found to be somewhat more effective than the equimolar amts. of 7-oxo-DHEA with which they were compared in each expt.

IT 250163-05-4P 357923-35-4P 357923-38-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and biol. activity of steroid glucuronosides, ethers, and

alkylcarbonates)

IT 357923-34-3P 357923-36-5P 357923-39-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and biol. activity of steroid glucuronosides, ethers, and alkylcarbonates)

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:247354 HCAPLUS

DOCUMENT NUMBER: 134:261560

TITLE: Therapeutic treatment of androgen receptor driven conditions using steroids or analogs

INVENTOR(S): Lardy, Henry A.; Marwah, Padma

PATENT ASSIGNEE(S): Hollis-Eden Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023405	A2	20010405	WO 2000-US26848	20000928
WO 2001023405	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000077363	A5	20010430	AU 2000-77363	20000928
EP 1228083	A2	20020807	EP 2000-967114	20000928
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			

PRIORITY APPLN. INFO.:
 US 1999-157275P P 19990930
 US 1999-157347P P 19990930
 US 1999-166116P P 19991116
 WO 2000-US26848 W 20000928

OTHER SOURCE(S): MARPAT 134:261560

AB A method is claimed to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to a subject, or delivering to the subject's tissues, an effective amt. of a steroid or steroid analogs. The steroid is specifically an analog of 1,3,5(10)-estratriene-17.alpha.-ethynyl-3.beta.,17.beta.-diol; 17.alpha.-ethynylandrostene-3.beta.,17.beta.-diol; 3.beta.,17.beta.-dihydroxyandrost-5-en-16-one; or 3.beta.-methylcarbonate-androst-5-en-7,17-dione. The androgen responsive disease is prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism or hirsutism. The method further comprises administering to the subject a second therapy; the second therapeutic agent is hydroxyflutamide, leuprolide, megestrol, diethylstilbesterol, aminoglutethimide, spironolactone, tamoxifen, cyproterone acetate, or bicalutamide.

IT 250163-05-4DP, analogs

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic treatment of androgen receptor driven conditions using
steroids or analogs)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:684497 HCAPLUS

DOCUMENT NUMBER: 131:332293

TITLE: Suppression of .DELTA.5-androstenediol-induced
androgen receptor transactivation by selective
steroids in human prostate cancer cells

AUTHOR(S): Chang, Hong-Chiang; Miyamoto, Hiroshi; Marwah, Padma;
Lardy, Henry; Yeh, Shuyuan; Huang, Ko-En; Chang,
Chawnshang

CORPORATE SOURCE: George Whipple Laboratory for Cancer Research,
Departments of Pathology, Urology, Radiation Oncology,
and the Cancer Center, University of Rochester Medical
Center, Rochester, NY, 14642, USA

SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1999), 96(20), 11173-11177
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors' earlier report suggested that androst-5-ene-3.beta.,7.beta.-
diol (.DELTA.5-androstenediol or Adiol) is a natural hormone with
androgenic activity and that two potent anti-androgens, hydroxyflutamide
(Eulexin) and bicalutamide (Casodex), fail to block completely the
Adiol-induced androgen receptor (AR) transactivation in prostate cancer
cells. Here, the authors report the development of a reporter assay to
screen several selective steroids with anti-Adiol activity. Among 22
derivs./metabolites of dehydroepiandrosterone, the authors found 4
steroids [no. 4, 1,3,5(10)-estratriene-17.alpha.-ethynyl-3,17.beta.-diol;
no. 6, 17.alpha.-ethynyl-androstene-diol; no. 8, 3.beta.,17.beta.-
dihydroxy-androst-5-ene-16-one; and no. 10, 3.beta.-methylcarbonate-
androst-5-ene-7,17-dione] that have no androgenic activity and could also
block the Adiol-induced AR transactivation in prostate cancer PC-3 cells.
Interestingly, these compds., in combination with hydroxyflutamide,
further suppressed the Adiol-induced AR transactivation. Reporter assays
further showed that these four anti-Adiol steroids have relatively lower
glucocorticoid, progesterone, and estrogenic activity. Together, these
data suggest some selective steroids might have anti-Adiol activity, which
may have potential clin. application in the battle against the
androgen-dependent prostate cancer growth.

IT 250163-05-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(androstenediol-induced androgen receptor transactivation suppression
by selective steroids in human prostate cancer cells)

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=>

=> fil caold

FILE 'CAOLD' ENTERED AT 11:22:13 ON 20 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>

=> s 17

L9 0 L7

=> fil reg

FILE 'REGISTRY' ENTERED AT 11:22:27 ON 20 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

=>

=> d ide can 17 tot

L7 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2003 ACS

RN 515159-71-4 REGISTRY

CN Androst-5-ene-7,17-dione, 3-[[[(1,1-dimethylethoxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C24 H34 O5

SR CA

LC STN Files: CAPLUS

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L7 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN 357923-39-8 REGISTRY
 CN Androst-5-ene-7,17-dione, 3-[[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C34 H36 O5
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN 357923-38-7 REGISTRY
 CN Androst-5-ene-7,17-dione, 3-[[[(octyloxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C28 H42 O5
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-36-5 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[2-methylpropoxy]carbonyl]oxy-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H34 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)


REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-35-4 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[(ethoxycarbonyl)oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C22 H30 O5
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN 357923-34-3 REGISTRY
 CN Androst-5-ene-7,17-dione, 3-[[[(2-propenyloxy)carbonyl]oxy]-, (3.beta.)-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H30 O5
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1957 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS
 RN 250163-05-4 REGISTRY
 CN Androst-5-ene-7,17-dione, 3-[(methoxycarbonyl)oxy]-, (3.beta.)- (9CI) (CA
 INDEX NAME)
 FS STEREOSEARCH
 MF C21 H28 O5
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 7 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:28973
 REFERENCE 2: 137:226941
 REFERENCE 3: 135:211172
 REFERENCE 4: 134:261560
 REFERENCE 5: 131:332293

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 11:24:57 ON 20 MAY 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 May 2003 VOL 138 ISS 21
 FILE LAST UPDATED: 19 May 2003 (20030519/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>
 => d stat que 115 nos
 L3 STR
 L5 156 SEA FILE=REGISTRY SSS FUL L3
 L6 STR
 L7 7 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
 L8 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L7
 L10 149 SEA FILE=REGISTRY ABB=ON PLU=ON L5 NOT L7
 L11 252 SEA FILE=HCAPLUS ABB=ON PLU=ON L10
 L14 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L11(L) (?PHARM? OR ?MEDIC? OR ?THERAP? OR ?DRUG? OR ?DISEAS? OR ?DISORDER?)
 L15 8 SEA FILE=HCAPLUS ABB=ON PLU=ON L14 NOT L8

=>
 =>
 => d ibib abs hitrn 115 1-8
 L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2003:223737 HCAPLUS
 DOCUMENT NUMBER: 138:215740
 TITLE: 7-Hydroxyl and 7-ketone derivatives of
 3-.beta.-hydroxyl steroid hormones for the treatment
 of inflammatory or functional diseases of the
 intestine
 INVENTOR(S): Seman, Michel; Criton, Marc
 PATENT ASSIGNEE(S): Laboratoires Mayoly Spindler, Fr.
 SOURCE: Fr. Demande, 19 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

```

-----
FR 2829697      A1      20030321      FR 2001-11904      20010914
WO 2003024460  A1      20030327      WO 2002-FR3109    20020912
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
    PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
    UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
    RU, TJ, TM
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
    CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
    PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
    NE, SN, TD, TG

```

PRIORITY APPLN. INFO.: FR 2001-11904 A 20010914

OTHER SOURCE(S): MARPAT 138:215740

AB Use of 7-hydroxylated and 7-ketonic derivs. of the 3.beta.-hydroxylated hormones steroids for the prepn. of a medicament intended to treat the inflammatory or functional diseases intestine like Crohn's disease, hemorrhagic colitis and the irritable bowel syndrome.

IT 566-19-8, 3.beta.-Hydroxy-5-androstene-7,17-dione

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(3-.beta.-hydroxylated steroid hormones derivs. for the treatment of inflammatory or functional **diseases** of the intestine)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:240572 HCAPLUS

DOCUMENT NUMBER: 136:257756

TITLE: Treatment of inflammatory bowel disease by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof

INVENTOR(S): Zenk, Ronald J.; Zenk, John L.

PATENT ASSIGNEE(S): Humanetics Corporation, USA

SOURCE: PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

```

PATENT NO.      KIND  DATE      APPLICATION NO.  DATE
-----
WO 2002024205  A1      20020328      WO 2001-US28895  20010918
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
    CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
    GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
    LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
    RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
    VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
    DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
    BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

```

AU 2001090989 A5 20020402 AU 2001-90989 20010918

PRIORITY APPLN. INFO.: US 2000-665640 A 20000919

WO 2001-US28895 W 20010918

AB Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, can be treated by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof.

IT 566-19-8 1449-61-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(treatment of inflammatory bowel disease by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:820640 HCAPLUS

DOCUMENT NUMBER: 134:95631

TITLE: Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers

AUTHOR(S): Davidson, Michael; Marwah, Ashok; Sawchuk, Ronald J.; Maki, Kevin; Marwah, Padma; Weeks, Charles; Lardy, Henry

CORPORATE SOURCE: Chicago Center for Clinical Research, Chicago, IL, USA
SOURCE: Clinical and Investigative Medicine (2000), 23(5), 300-310

CODEN: CNVMDL; ISSN: 0147-958X

PUBLISHER: Canadian Medical Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Studies were carried out to evaluate the safety and pharmacokinetics of 3-acetyl-7-oxo-DHEA (3.beta.-acetoxyandrost-5-ene-7,17-dione) given orally. The study consisted of a randomized, double blind, placebo-controlled, escalating dose study in the Chicago Center for Clin. Research involving 22 healthy men. The participants received placebo or 3-acetyl-7-oxo-DHEA at 50 mg/d for 7 days followed by a 7-day washout; 100 mg/d for 7 days followed by a 7-day washout; and 200 mg/d for 28 days. Safety parameters, evaluated at each dose level, included measurement of total testosterone, free testosterone, dihydrotestosterone, estradiol, cortisol, thyroxine and insulin levels. Analyses for 7-oxo-DHEA-3.beta.-sulfate (DHEA-S), the only detectable metabolic product of the administered steroid, were conducted on plasma drawn from all subjects at 0.25, 0.5, 1, 2, 4, 6 and 12 h after the final 100 mg dose of 3.beta.-acetyl-7-oxo-DHEA. There were no differences in the clin. lab. values or in reported minor adverse experiences, between treatment and placebo groups. In general, blood hormone concns. were unaffected by the treatment with 3.beta.-acetyl-7-oxo-DHEA and remained within the normal range. No changes in vital signs, blood chem. or urinalysis occurred during treatment with 3.beta.-acetyl-7-oxo-DHEA compared to placebo. The administered steroid was not detected in the blood but was rapidly converted to 7-oxo-DHEA-S, the concns. of which were proportional to dose. This steroid sulfate did not accumulate; plasma concns. 12 h after the 3.beta.-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 .mu.g/L resp. The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 h; the mean half life was 2.17 h. The apparent clearance averaged 172 L/h, and the apparent mean vol. of distribution was 540 L. These results indicate that 3.beta.-acetyl-7-oxo-DHEA is safe and well tolerated in normal healthy men at doses up to 200 mg/d for 4 wk.

IT 1449-61-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dehydroepiandrosterone acetyloxo derive safety and pharmacokinetics and metab. and endocrine effects in men)

IT 4121-96-4

RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)

(dehydroepiandrosterone acetyloxo derive safety and pharmacokinetics and metab. and endocrine effects in men)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:444298 HCAPLUS

DOCUMENT NUMBER: 133:203125

TITLE: 7-Hydroxydehydroepiandrosterone - a natural
antiglucocorticoid and a candidate for steroid
replacement therapy?

AUTHOR(S): Hampl, R.; Lapcik, O.; Hill, M.; Klak, J.; Kasal, A.;
Novacek, A.; Sterzl, I.; Sterzl, J.; Starka, L.

CORPORATE SOURCE: Institute of Endocrinology, Prague, Czech Rep.

SOURCE: Physiological Research (Prague) (2000), 49(Suppl. 1),
S107-S112

CODEN: PHRSEJ; ISSN: 0862-8408

PUBLISHER: Institute of Physiology, Academy of Sciences of the
Czech Republic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 7-Hydroxylated metabolites of dehydroepiandrosterone (DHEA) are believed
to be responsible for at least some immunomodulatory and
antiglucocorticoid effects of DHEA and hence are considered candidates for
hormone replacement therapy. Our expts. in vitro brought the evidence
that 3.beta.,7.beta.-dihydroxy-5-androsten-3-one (7.beta.-OH-DHEA), but
not DHEA and its 7.alpha.-hydroxyisomer, could counteract the
immunosuppressive effect of dexamethasone on the formation of plaques in
culture of murine spleen lymphocytes. In another expt., DHEA and after a
3-wk pause 3.beta.-hydroxy-5-androstene-7,17-dione (7-oxo-DHEA) were
applied transdermally to 6 male volunteers on 5 consecutive days. Blood
levels of DHEA, its 7-hydroxylated metabolites, and in the first case also
dehydroepiandrosterone sulfate (DHEAS), were measured before, during and
one day after the end of treatment. Application of DHEA increased
significantly not only DHEA and DHEAS, but also its both 7-hydroxyisomers.
Application of 7-oxo-DHEA also led to a significant increase of both
7-hydroxyisomers of DHEA, with 7.beta.-OH-DHEA being the preferred
metabolite the concn. of which was increased more than three times.

IT 566-19-8, 3.beta.-Hydroxy-5-androstene-7,17-dione

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)

(7-hydroxydehydroepiandrosterone, a natural antiglucocorticoid and
possible candidate for steroid replacement therapy)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:208596 HCAPLUS

DOCUMENT NUMBER: 120:208596

TITLE: Treatment of Alzheimer's disease and modulation of
immune system with .DELTA.5-androstenes

INVENTOR(S): Lardy, Henry A.

PATENT ASSIGNEE(S): Humanetics Corp., USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9403176	A1	19940217	WO 1993-US7327	19930802
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP,				

KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5292730	A	19940308	US 1992-922850	19920731
AU 9349970	A1	19940303	AU 1993-49970	19930802
JP 08505602	T2	19960618	JP 1993-505536	19930802
JP 2762315	B2	19980604		
EP 746322	A1	19961211	EP 1993-919879	19930802
EP 746322	B1	20000119		

R: BE, DE, ES, FR, GB, IT, NL, SE

PRIORITY APPLN. INFO.:
 US 1992-922850 A 19920731
 US 1990-575156 B1 19900829
 US 1992-867288 A2 19920410
 WO 1993-US7327 W 19930802

AB Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a therapeutic amt. of a .DELTA.5-androstene-3.beta.-ol-17-one having a C7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis. 7-Oxo DHEA (I) was prepd. from DHEA acetate and tested in mice. I did not induce clin. apparent toxicity. I enhanced the immune response to an influenza virus when the normal response in mice was less than optimal.

IT **1449-61-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction of, in prepn. of androsteneolone for treating Alzheimer's **disease** and modulating immune system)

IT **566-19-8P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of and Alzheimer's **disease** treatment and immune system modulation with)

L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:199311 HCAPLUS

DOCUMENT NUMBER: 110:199311

TITLE: Quantitative thin-layer chromatographic analysis of dehydroepiandrosterone enanthate and estradiol valerate in pharmaceutical preparations and blood

AUTHOR(S): Amin, M.

CORPORATE SOURCE: Fac. Pharm., Al Azhar Univ., Cairo, Egypt

SOURCE: Pharmazeutische Industrie (1989), 51(1), 109-12
 CODEN: PHINAN; ISSN: 0031-711X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A simultaneous direct, quant., TLC-densitometric method for detn. of dehydroepiandrosterone enanthate (I) and estradiol valerate (II) in tablets, oily solns., and in blood is described. TLC was carried out on pre-coated silica gel 60 F254 gel plates and the spots were measured directly by the reflection method following development with 2,4-dinitrophenylhydrazine at 550 and 510 nm, for I and II, resp. The method is characterized by a short anal. time and good sensitivity, selectivity, and accuracy, and is therefore suitable for quality control, stability investigations, and pharmacokinetics studies. The relative std. deviation is 3.7% for I and 2.9% for II. A degrdn. product of I, 3.beta.-heptanoyloxy-5-androstene-7,17-dione, may also be detd. by this method.

IT **53926-88-8**

RL: ANT (Analyte); ANST (Analytical study)
 (detn. of, in blood plasma and **pharmaceuticals** by TLC-densitometry)

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1979:568998 HCAPLUS

DOCUMENT NUMBER: 91:168998
 TITLE: Effect of chorionic gonadotropin on the urinary excretion of testosterone and other androgens in healthy males and in males with coronary atherosclerosis
 AUTHOR(S): Marenich, L. P.
 CORPORATE SOURCE: Sverdl. Med. Inst., Sverdlovsk, USSR
 SOURCE: Kardiologiya (1979), 19(6), 76-9
 CODEN: KARDA2; ISSN: 0022-9040
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB Chorionic gonadotropin [9002-61-3] (3000 units/day) injected i.m. for 3 days into normal men increased urinary excretion of testosterone [58-22-0], epitestosterone [481-30-1], androstenedione [63-05-8], and 7-keto-dehydroepiandrosterone [566-19-8]. In patients with ischemic heart **disease** this stimulatory effect of chorionic gonadotropin was generally much reduced. Thus, male patients with ischemic heart **disease** can also have decreased testis function.

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1961:94761 HCAPLUS
 DOCUMENT NUMBER: 55:94761
 ORIGINAL REFERENCE NO.: 55:17871f-g
 TITLE: Isolation of 5-androstene-7,17-dione-3.beta.-ol sulfuric ester from peripheral blood plasma and adrenal venous plasma
 AUTHOR(S): Baulieu, E. E.; Emiliozzi, R.; Corpechot, C.
 CORPORATE SOURCE: Fac. med., Paris
 SOURCE: Experientia (1961), 17, 110-11
 DOCUMENT TYPE: Journal
 LANGUAGE: French

AB 5-Androstene-7,17-dione-3.beta.-ol sulfuric ester was isolated from the peripheral venous blood plasma of several virilized women, in adrenal venous plasma of one of them, and also in 3 cases of adrenal tumor.
 IT **4121-96-4**, Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, hydrogen sulfate
 (in blood plasma in adrenal **disorder**)

=>
 =>

=> select hit rn l15 1-8
 E1 THROUGH E4 ASSIGNED

=>
 =>

=> fil reg
 FILE 'REGISTRY' ENTERED AT 11:25:17 ON 20 MAY 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2
 DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

```
=>
=>
=> s el-e4
      1 566-19-8/BI
        (566-19-8/RN)
      1 1449-61-2/BI
        (1449-61-2/RN)
      1 4121-96-4/BI
        (4121-96-4/RN)
      1 53926-88-8/BI
        (53926-88-8/RN)
L16   4 (566-19-8/BI OR 1449-61-2/BI OR 4121-96-4/BI OR 53926-88-8/BI)


=>
=>
```

```
=> d ide can l15 1-4
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:end
```

```
=> d ide can l16 1-4
```

```
L16 ANSWER 1 OF 4  REGISTRY  COPYRIGHT 2003 ACS
RN   53926-88-8  REGISTRY
CN   Androst-5-ene-7,17-dione, 3-[(1-oxoheptyl)oxy]-, (3.beta.)- (9CI) (CA
      INDEX NAME)
OTHER NAMES:
CN   3.beta.-Heptanoyloxy-5-androstene-7,17-dione
FS   STEREOSEARCH
MF   C26 H38 O4
LC   STN Files:  BEILSTEIN*, CA, CAPLUS, USPATFULL
      (*File contains numerically searchable property data)
```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:28973

REFERENCE 2: 110:199311

REFERENCE 3: 82:47693

L16 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS

RN 4121-96-4 REGISTRY

CN Androst-5-ene-7,17-dione, 3-(sulfooxy)-, (3.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, hydrogen sulfate (6CI, 7CI, 8CI)

OTHER NAMES:

CN 7-Oxo-5,6-dehydroepiandrosterone sulfate


FS STEREOSEARCH

MF C19 H26 O6 S

CI COM

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1957 TO DATE)

15 REFERENCES IN FILE CAPLUS (1957 TO DATE)

5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:180934

REFERENCE 2: 138:28973

REFERENCE 3: 137:303980

REFERENCE 4: 136:304231

REFERENCE 5: 134:95631

REFERENCE 6: 130:276909

REFERENCE 7: 126:6438

REFERENCE 8: 125:41730

REFERENCE 9: 76:124618

REFERENCE 10: 65:58271

L16 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS

RN 1449-61-2 REGISTRY

CN Androst-5-ene-7,17-dione, 3-(acetyloxy)-, (3.beta.)- (9CI) (CA INDEX

NAME)

OTHER CA INDEX NAMES:

CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, acetate (6CI, 7CI, 8CI)

OTHER NAMES:

CN 3.beta.-Acetoxy-5-androsten-7,17-dione

CN 3.beta.-Acetoxyandrost-5-ene-7,17-dione

CN 5-Androsten-3.beta.-ol-7,17-dione acetate

CN 7-Keto Naturalean

FS STEREOSEARCH


MF C21 H28 O4

LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, IFICDB,

IFIPAT, IFIUDB, TOXCENTER, USPATFULL

(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

82 REFERENCES IN FILE CA (1957 TO DATE)

82 REFERENCES IN FILE CAPLUS (1957 TO DATE)

14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:192855

REFERENCE 2: 138:158820

REFERENCE 3: 138:158560

REFERENCE 4: 138:158559

REFERENCE 5: 138:56127

REFERENCE 6: 138:44508

REFERENCE 7: 138:28973

REFERENCE 8: 137:389043

REFERENCE 9: 137:289381

REFERENCE 10: 137:169693

L16 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS

RN 566-19-8 REGISTRY

CN Androst-5-ene-7,17-dione, 3-hydroxy-, (3.beta.)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy- (8CI)


OTHER NAMES:

CN 3.beta.-Hydroxy-5-androstene-7,17-dione

CN 5-Androsten-3.beta.-ol-7,17-dione

CN 7-Keto-DHEA
 CN 7-Ketodehydroepiandrosterone
 CN 7-Oxodehydroepiandrosterone
 FS STEREOSEARCH
 MF C19 H26 O3
 LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CSCHEM,
 IFICDB, IFIPAT, IFIUDB, MEDLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

130 REFERENCES IN FILE CA (1957 TO DATE)
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 133 REFERENCES IN FILE CAPLUS (1957 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE	1:	138:248958
REFERENCE	2:	138:215740
REFERENCE	3:	138:192855
REFERENCE	4:	138:180934
REFERENCE	5:	138:158820
REFERENCE	6:	138:158560
REFERENCE	7:	138:158559
REFERENCE	8:	138:158558
REFERENCE	9:	138:44508
REFERENCE	10:	138:28973